Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBER Reviewers To Remain Accessible Post-Merger, CDER Tells BLA Sponsors

Executive Summary

CBER product reviewers will remain accessible to biologics sponsors following the consolidation of the agency's drug and biologics centers, CDER Deputy Director Steven Galson said
Advertisement

Related Content

FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
FDA Approves 9 NMEs, 6 BLAs In First Half ‘03, On Track To Exceed 2002 Total
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
CBER/CDER Consolidation: Weiss Named Acting Director Of New ODE VI
Advertisement
UsernamePublicRestriction

Register

PS042030

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel